Why the study?
SERCA dysfunction pathologically contributes to cardiomyopathy and heart failure, and glycogen synthase kinase 3 regulates SERCA function alongside phospholamban.
GSK3 regulation of SERCA function via PLN and SERCA2a expression represents a potential therapeutic target for cardiomyopathies and heart failure.
Emphasizes SERCA-PLN axis in cardiomyopathy; leaves open targeted therapeutic translation.
Cardiac contractile function is largely mediated by the regulation of Ca 2+ cycling throughout the lifespan. The sarco(endo)plasmic reticulum Ca 2+ ATPase (SERCA) pump is paramount to cardiac Ca 2+ regulation, and it is well established that SERCA dysfunction pathologically contributes to cardiomyopathy and heart failure. Phospholamban (PLN) is a well-known inhibitor of the SERCA pump and its regulation of SERCA2a—the predominant cardiac SERCA isoform—contributes significantly to proper cardiac function. Glycogen synthase kinase 3 (GSK3) is a serine/threonine kinase involved in several metabolic pathways, and we and others have shown that it regulates SERCA function. In this mini-review, we highlight the underlying mechanisms behind GSK3’s regulation of SERCA function specifically discussing changes in SERCA2a and PLN expression and its potential protection against oxidative stress. Ultimately, these recent findings that we discuss could have clinical implications in the treatment and prevention of cardiomyopathies and heart failure.
No takes yet. Share an insight, caveat, or question.
Hamstra et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: